Gilead Sciences is still deciding whether to combine its antiviral GS-7977 for hepatitis C virus (HCV) with Bristol-Myers Squibb's daclatasvir in a phase 3 trial, notwithstanding impressive results using the investigational drugs together. The phase 2 data presented in April at the annual meeting of the European Association for the Study of the Liver in Barcelona showed that the all-oral combination achieved early cure rates in 100% of genotype 1 patients and in 91% of genotype 2 and 3 patients four weeks after treatment without using interferon. Results so far place the GS-7977/daclatasvir combination ahead of the game, however, Bristol's CEO Lamberto Andreotti reportedly said the companies have opposing views on how to proceed. BMS's daclatasvir is a NS5A inhibitor, and Foster City, California–based Gilead already has one of those and is likely to develop its own in-house combination. Gilead's spokesperson Erin Rau says they are currently evaluating the newly released data. “We're going to do that, and look at the best option or options for proceeding as quickly as possible to advance the best all-oral regimen.” Gilead gained GS-7977, a nucleotide NS5B polymerase inhibitor, from its $10.8 billion acquisition of Princeton, New Jersey–based Pharmasset (Nat. Biotechnol. 30, 122, 2012) and has six other drugs in clinical development for HCV, including phase 2 NS5A inhibitor GS-5885. BMS spokesperson Sonia Choi says the New York company is currently working on four other combinations with daclatasvir using its NS5B nucleotide BMS-986094.